Synthesis and cytotoxicity evaluation of novel podophyllotoxin derivatives

Archiv der Pharmazie

Volumn 344, Issue 11, 2011, Pages 735-740

  Chengniu, Wang ^a   Zhonghua, Wu ^a   Yu, Zhao ^a   Chunyan, Ni ^a   Xiaodong, Zhao ^b   Li, Zhu ^a  

^a NANTONG UNIVERSITY   (China)

^b ZHEJIANG OCEAN UNIVERSITY   (China)

Author keywords

Benzylamino derivatives; Cytotoxicity; Podophyllotoxin

Indexed keywords

4BETA (2'' CHLORO BENZIMIDOYL) 4 DEOXYPODOPHYLLOTOXIN; 4BETA (2'' CHLORO BENZYLAMINO) 4 DEOXYPODOPHYLLOTOXIN; 4BETA (4'' BENZIMIDOYL) 4 DEOXYPODOPHYLLOTOXIN; 4BETA (4'' BENZYLAMINO) 4 DEOXYPODOPHYLLOTOXIN; 4BETA (4'' BROMO BENZIMIDOYL) 4 DEOXYPODOPHYLLOTOXIN; 4BETA (4'' BROMO BENZYLAMINO) 4 DEOXYPODOPHYLLOTOXIN; 4BETA (4'' CHLORO BENZIMIDOYL) 4 DEOXYPODOPHYLLOTOXIN; 4BETA (4'' CHLORO BENZYLAMINO) 4 DEOXYPODOPHYLLOTOXIN; 4BETA (4'' FLUORO BENZIMIDOYL) 4 DEOXYPODOPHYLLOTOXIN; 4BETA (4'' FLUORO BENZYLAMINO) 4 DEOXYPODOPHYLLOTOXIN; 4BETA (4'' METHOXYL BENZIMIDOYL) 4 DEOXYPODOPHYLLOTOXIN; 4BETA (4'' METHOXYL BENZYLAMINO) 4 DEOXYPODOPHYLLOTOXIN; 4BETA (4'' METHYL BENZIMIDOYL) 4 DEOXYPODOPHYLLOTOXIN; 4BETA (4'' METHYL BENZYLAMINO) 4 DEOXYPODOPHYLLOTOXIN; PODOPHYLLOTOXIN DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER INHIBITION; CARBON NUCLEAR MAGNETIC RESONANCE; CYTOTOXICITY; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; HUMAN CELL; IC 50; INFRARED SPECTROSCOPY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HCT116 CELLS; HEP G2 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; NEOPLASMS; PODOPHYLLOTOXIN; SPECTRUM ANALYSIS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 80355145133     PISSN: 03656233     EISSN: 15214184     Source Type: Journal    
DOI: 10.1002/ardp.201100095     Document Type: Article

References (22)

1. H. W. Lin, K. H. Kwok, P. M. Doran, Biotechnol. Prog. 2003, 19, 1417-1426.
2. H. L. Byron, S. T. Musial, M. G. Brattain, Biochem. 1984, 23, 1183-1188.
3. H. Xu, M. Lv, X. Tian, Curr. Med. Chem. 2009, 16, 327-349.
4. B. F. Issell, Cancer Chemother. Pharmacol. 1982, 7, 73-80.
5. C. P. Belani, L. A. Doyle, J. Aisner, Cancer Chemother. Pharmacol. 1994, 34, 118-126.
6. Y. Pommier, M. R. Fesen, F. Goldwasser, Cancer Chemother. Biother. 1996, 435-461.
7. P. Meresse, E. Dechaux, C. Monneret, E. Bertounesque, Curr. Med. Chem. 2004, 11, 2443-2466.
8. Y.-J. You, Curr. Pharm. Des. 2005, 11, 1695-1717.
9. A. Kamal, B. A. Kumar, P. Suresh, A. Juvekar, S. Zingde, Bioorg. Med. Chem. 2011, 19 (9), 2975-2979.
10. Y.-Q. Liu, L. Yang, X. Tian, Curr. Bioact. Compd. 2007, 3, 37-66.
11. B. A. Bhat, P. Bhaskar Reddy, S. K. Kumar Agrawal, A. K. Saxena, H. M. Sampath Kumar, G. N. Qazi, Eur. J. Med. Chem. 2008, 43, 2067-2072.
12. D. M. Reddy, J. Srinivas, G. Chashoo, A. K. Saxena, H. M. Sampath Kumar, Eur. J. Med. Chem. 2011, 46 (6), 1983-1991.
13. A. Kamal, B. A. Kumar, P. Suresh, N. Shankaraiah, M. Shiva Kumar, Bioorg. Med. Chem. Lett. 2011, 21, 350-353.
14. Z.-W. Zhang, J.-Q. Zhang, L. Hui, S.-W. Chen, X. Tian, Eur. J. Med. Chem. 2010, 45, 1673-1677.
15. Y. Zhao, C.-N. Wang, Z.-H. Wu, J.-H. Fang, L. Zhu, Invest. New Drugs 2011, published online. DOI: 10.1007/s10637-010-9508-1
16. A. Kamal, B. A. Kumar, P. Suresh, S. Kumar Agrawal, G. Chashoo, S. K. Singh, A. K. Saxena, Bioorg. Med. Chem. 2010, 18, 8493-8500.
17. A. Kamal, B. A. Kumar, M. Arifuddin, Tetrahedron Lett. 2003, 44, 8457-8459.
18. H. Chang, K.-G. Shyu, C.-C. Lee, S.-C. Tsai, B.-W. Wang, Y.-H. Lee, S.-K. Lina, Biochem. Biophys. Res. 2003, 302, 95-100.
19. A. Kamal, N. Lakshnai Gayatri, Tetrahedron Lett. 1996, 37, 335-3362.
20. L. Daley, P. Meresse, E. Bertounesque, C. Monneret, Tetrahedron Lett. 1997, 38, 2673-2676.
21. S. W. Chen, Y. H. Wang, Y. Jin, X. Tian, Y. T. Zheng, D. Q. Luo, Y. Q. Tu, Bioorg. Med. Chem. Lett. 2007, 17, 2091-2095.
22. X. M. Zhou, Z. Q. Wang, J. Y. Chang, H. X. Chen, Y. C. Cheng, K. H. Lee, J Med Chem. 1991, 34, 3346-3352.